DossierENTITY

French biotech

Coverage of French biotech in the Nexus archive.

Earliest in view: Jul 10 · 10:10 UTCMost recent: Jul 10 · 10:10 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJul 10 · 10:10 UTCCNBC TOP
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax secured $920 million in funding, enabling the French biotech company to prepare for an independent U.S. launch without relying on a buyer. The funds will cover operations through 2029.